Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.
Follow ARCT
Arcturus Therapeutics Holdings Inc. (ARCT) P/E ratio
Arcturus Therapeutics Holdings Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 67.4× (February 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 49.1× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ENTA Enanta Pharmaceuticals, Inc. compare | n/m |
| IRD Opus Genetics, Inc. compare | n/m |
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| ARCT Arcturus Therapeutics Holdings Inc. | n/m |
| AGEN Agenus Inc. compare | 2.3× |
| CYPH Cypherpunk Technologies Inc. compare | 4.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)